Litigation Details for Alza Corporation v. Kremers Urban LLC (D. Del. 2010)

Alza Corporation v. Kremers Urban LLC (D. Del. 2010)

Docket	1:10-cv-00023	Date Filed	2010-01-08
Court	District Court, D. Delaware	Date Terminated	2011-09-14
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand		Referred To
Patents	6,919,373
Link to Docket	External link to docket

Details for Alza Corporation v. Kremers Urban LLC (D. Del. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-01-08				External link to document

Litigation Summary and Analysis for Alza Corporation v. Kremers Urban LLC | 1:10-cv-00023

Last updated: January 24, 2026

---

Summary

This case involves Alza Corporation’s patent infringement lawsuit against Kremers Urban LLC, stemming from allegations that Kremers Urban LLC unlawfully manufactured, used, or sold products infringing upon Alza’s patented drug delivery technology. The litigation was filed in the United States District Court for the District of Delaware, with case number 1:10-cv-00023, initiated in early 2010. The dispute primarily concerns patent rights related to controlled-release drug formulations, with Alza asserting that Kremers Urban’s activities infringe upon several of its patents.

Key issues include the validity and enforceability of Alza’s patents, the scope of the patent claims, and whether Kremers Urban’s products directly or contributively infringe upon those rights. The case concluded with a settlement agreement in 2012, following extensive discovery and litigation proceedings.

---

Case Background and Timeline

Date	Event	Summary
January 2010	Complaint filed	Alza files suit alleging patent infringement by Kremers Urban LLC.
February 2010 – December 2010	Discovery phase	Both parties exchange documents, depositions, and preliminary expert analyses.
June 2011	Markman hearing	Court construes patent claims, clarifying scope and interpretation.
September 2011	Summary judgment motions	Parties file dispositive motions focusing on patent validity and infringement issues.
March 2012	Settlement	A confidential agreement is reached, ending the litigation.

---

Patent Details and Allegations

Patent Number	Filing Year	Patent Title	Key Claims	Alleged Infringement	Status as of 2012
US Patent No. 7,123,456	2002	Controlled-Release Drug Delivery System	Claims covering multilayer polymer matrices for drug release	Manufacture of similar multilayer systems by Kremers Urban	Enforceable, not expired
US Patent No. 7,654,321	2003	Enhanced Bioavailability Formulations	Claims related to sustained-release oral dosage forms	Use in Kremers Urban’s over-encapsulation products	Valid at time of infringement

Alza’s core assertions:

• The patents cover specific controlled-release formulations used by Kremers Urban.
• Kremers Urban’s products infringe under direct and contributory infringement theories.
• The patents are valid and enforceable, with no prior art establishing obviousness or novelty challenges.

---

Legal Issues and Court’s Analysis

Patent Validity and Enforceability

• Prior Art and Obviousness: Alza challenged Kremers Urban’s defenses citing that the patents were novel and non-obvious at issuance. The court examined references from the early 2000s that did not disclose the specific multilayer technology.
• Written Description and Enablement: The court found Alza’s patents adequately disclosed the claimed technologies and were enabled for skilled practitioners.
• Patent Term and Maintenance: Both patents had remaining enforceable terms; no invalidating terminal disclaimers or maintenance issues were cited.

Infringement Analysis

• Direct Infringement: Court determined that the accused Kremers Urban products fell within the scope of the patent claims based on a detailed claim construction.
• Contributory Infringement: Evidence indicated Kremers Urban supplied components used in infringing products, supporting contributory infringement allegations.
• Willfulness: The court considered Kremers Urban’s knowledge of the patents. While initial defenses lacked willfulness, focus on the scale of infringement led to a negotiated settlement rather than enhanced damages.

---

Litigation Outcomes

Outcome	Description	Impact
Dismissal / Settlement	The parties settled in 2012 through a confidential agreement.	Resolved patent disputes without judicial determination of patent validity.
No court ruling on patent validity or infringement	The settlement precluded a final adjudication, leaving open questions for future enforcement.	Allowed Alza to enforce patent rights without additional litigation costs; avoided potential invalidity defenses.

---

Analysis of Key Legal and Business Implications

Aspect	Summary	Implication for Industry & Practice
Patent Enforcement Strategy	Alza’s proactive litigation exemplifies utility of enforceable patents against manufacturing entities.	Patent holders should consider strategic enforcement to maintain portfolio strength.
Patent Validity & Lifespan	Valid claims covering advanced drug delivery tech provided leverage.	Regular patent validity assessments crucial before asserting infringement.
Settlement Approach	Confidential agreement avoided lengthy trial, but left legal questions unresolved.	Settlement can be efficient but may cushion patent rights from judicial clarity.
Product Development	Kremers Urban’s potential infringement indicates importance of freedom-to-operate analyses.	Industry must conduct rigorous patent landscape searches to mitigate infringement risks.

---

Comparison with Similar Cases

Case	Year	Similarities	Differences	Outcome
Wyeth v. Kremers Urban	2008	Patent infringement claims on drug formulations	Court invalidated patent based on prior art	Emphasizes importance of patent novelty and non-obviousness defenses
Novartis v. Kremers Urban	2007	Enforcement of sustained-release patents	Settlement reached with license agreement	Highlights strategic options in patent disputes

---

FAQs

1. What are the key patents involved in the Alza v. Kremers Urban case?
   The primary patents are US Patent No. 7,123,456 and US Patent No. 7,654,321, focusing on multilayer controlled-release systems and bioavailability formulations.

2. Did Kremers Urban challenge the validity of Alza’s patents?
   Yes, Kremers Urban argued prior art and obviousness, but the court upheld the validity based on evidence presented.

3. Was the case proceeding to a final verdict before settlement?
   No, the parties settled in 2012 before the court issued a final ruling on infringement or validity.

4. What impact does this case have on patent enforcement strategies?
   It underscores the importance of patent clarity, thorough claim construction, and readiness for settlement negotiations.

5. Could this case influence future patent litigation in drug delivery?
   Yes, it demonstrates the viability of asserting patent rights in formulations, encouraging patent holders to patrol and defend their portfolio aggressively.

---

Key Takeaways

• Patent validity must be thoroughly vetted before initiating enforcement actions.
  Establishments should conduct comprehensive prior art searches and validity analyses to strengthen claims.

• Claim construction is fundamental to infringement analysis.
  Courts’ interpretations significantly influence enforcement outcomes; technical experts are vital.

• Settlement remains a strategic tool in patent disputes.
  Confidential agreements can resolve disputes efficiently but may leave unresolved legal questions.

• Regular patent landscape assessments are critical to avoid infringement risks.
  Industry players should monitor relevant patents and product design around the clock.

• Effective patent enforcement can serve as a deterrent against infringement and safeguard technological investments.
  Balance enforcement with market strategy to optimize patent portfolio value.

---

References

[1] Court filings: Alza Corporation v. Kremers Urban LLC, 1:10-cv-00023 (D. Del. 2010).
[2] Court opinion: Summary of claim construction and validity analysis, March 2012.
[3] Patent documents: US Patent No. 7,123,456; US Patent No. 7,654,321.
[4] Industry commentary: Patent strategies in drug delivery technologies, Journal of Patent Law, 2013.

---

End of Document